Consequently, osimertinib has become the standard of care for first-line treatment of EGFR-mutant NSCLC, demonstrating superior progression-free survival and overall survival compared to earlier generation TKIs10,11. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.